+

WO2006108965A3 - Antagonistes npy, preparation et utilisations - Google Patents

Antagonistes npy, preparation et utilisations Download PDF

Info

Publication number
WO2006108965A3
WO2006108965A3 PCT/FR2006/000829 FR2006000829W WO2006108965A3 WO 2006108965 A3 WO2006108965 A3 WO 2006108965A3 FR 2006000829 W FR2006000829 W FR 2006000829W WO 2006108965 A3 WO2006108965 A3 WO 2006108965A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
npy
preparation
antagonists
therapeutic
Prior art date
Application number
PCT/FR2006/000829
Other languages
English (en)
Other versions
WO2006108965A2 (fr
Inventor
Iuliana Botez
Christelle David-Basei
Nelly Gourlaouen
Eric Nicolai
Fabrice Balavoine
Gerard Valette
Gal Claudine Serradeil-Le
Original Assignee
Cerep
Iuliana Botez
Christelle David-Basei
Nelly Gourlaouen
Eric Nicolai
Fabrice Balavoine
Gerard Valette
Gal Claudine Serradeil-Le
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2008505929A priority Critical patent/JP2008538749A/ja
Priority to EP06743700A priority patent/EP1879887A2/fr
Priority to US11/918,470 priority patent/US20090233910A1/en
Priority to MX2007012847A priority patent/MX2007012847A/es
Priority to AU2006234413A priority patent/AU2006234413A1/en
Priority to AP2007004218A priority patent/AP2007004218A0/xx
Priority to EA200800157A priority patent/EA200800157A1/ru
Priority to CA002604773A priority patent/CA2604773A1/fr
Application filed by Cerep, Iuliana Botez, Christelle David-Basei, Nelly Gourlaouen, Eric Nicolai, Fabrice Balavoine, Gerard Valette, Gal Claudine Serradeil-Le filed Critical Cerep
Publication of WO2006108965A2 publication Critical patent/WO2006108965A2/fr
Publication of WO2006108965A3 publication Critical patent/WO2006108965A3/fr
Priority to TNP2007000376A priority patent/TNSN07376A1/en
Priority to IL186601A priority patent/IL186601A0/en
Priority to NO20075322A priority patent/NO20075322L/no
Priority to EC2007007894A priority patent/ECSP077894A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/06—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing isoquinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne de nouveaux composés, leur préparation et leurs utilisations, notamment thérapeutiques. Elle concerne plus particulièrement des composés dérivés présentant au moins deux cycles aromatiques, leur préparation et leurs utilisations, notamment dans le domaine de la santé humaine ou animale. Ces composés ont une affinité pour les récepteurs biologiques du neuropeptide Y, NPY, présents dans les systèmes nerveux central et périphérique. Les composés selon l'invention sont préférentiellement des antagonistes de NPY et plus particulièrement des antagonistes du sous-type NPY Y1, et sont donc utilisables dans le traitement thérapeutique ou prophylactique de tout désordre impliquant NPY. La présente invention concerne également des compositions pharmaceutiques comprenant de tels composés, leur préparation et leurs utilisations, ainsi que des méthodes de traitement utilisant lesdits composés.
PCT/FR2006/000829 2005-04-15 2006-04-14 Antagonistes npy, preparation et utilisations WO2006108965A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
EA200800157A EA200800157A1 (ru) 2005-04-15 2006-04-14 Антагонисты npy, способ их получения и применение
US11/918,470 US20090233910A1 (en) 2005-04-15 2006-04-14 Npy antagonists, preparation and uses
MX2007012847A MX2007012847A (es) 2005-04-15 2006-04-14 Antagonistas de npy, preparacion y usos.
AU2006234413A AU2006234413A1 (en) 2005-04-15 2006-04-14 NPY antagonists, preparation and use
AP2007004218A AP2007004218A0 (en) 2005-04-15 2006-04-14 NPY antagonists, preparation and use
JP2008505929A JP2008538749A (ja) 2005-04-15 2006-04-14 Ｎｐｙ拮抗物質、調製および使用
EP06743700A EP1879887A2 (fr) 2005-04-15 2006-04-14 Antagonistes npy, preparation et utilisations
CA002604773A CA2604773A1 (fr) 2005-04-15 2006-04-14 Antagonistes npy, preparation et utilisations
TNP2007000376A TNSN07376A1 (en) 2005-04-15 2007-10-05 Npy antagonists, preparation and use
IL186601A IL186601A0 (en) 2005-04-15 2007-10-11 Npy antagonists, preparation and use
NO20075322A NO20075322L (no) 2005-04-15 2007-10-17 NPY antagonister, samt femstilling og anvendelse av samme
EC2007007894A ECSP077894A (es) 2005-04-15 2007-11-13 Antagonistas de npy, preparación y usos

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0503795 2005-04-15
FR0503795A FR2884516B1 (fr) 2005-04-15 2005-04-15 Antagonistes npy, preparation et utilisations

Publications (2)

Publication Number Publication Date
WO2006108965A2 WO2006108965A2 (fr) 2006-10-19
WO2006108965A3 true WO2006108965A3 (fr) 2007-03-29

Family

ID=35447654

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000829 WO2006108965A2 (fr) 2005-04-15 2006-04-14 Antagonistes npy, preparation et utilisations

Country Status (19)

Country Link
US (1) US20090233910A1 (fr)
EP (1) EP1879887A2 (fr)
JP (1) JP2008538749A (fr)
KR (1) KR20080009112A (fr)
CN (1) CN101198604A (fr)
AP (1) AP2007004218A0 (fr)
AU (1) AU2006234413A1 (fr)
CA (1) CA2604773A1 (fr)
CR (1) CR9514A (fr)
EA (1) EA200800157A1 (fr)
EC (1) ECSP077894A (fr)
FR (1) FR2884516B1 (fr)
IL (1) IL186601A0 (fr)
MA (1) MA29444B1 (fr)
MX (1) MX2007012847A (fr)
NI (1) NI200700260A (fr)
NO (1) NO20075322L (fr)
TN (1) TNSN07376A1 (fr)
WO (1) WO2006108965A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889690B2 (en) 2007-04-27 2014-11-18 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
GB0512091D0 (en) * 2005-06-14 2005-07-20 Novartis Ag Organic compounds
US8334290B2 (en) * 2005-10-31 2012-12-18 Merck Sharp & Dohme Corp. CETP inhibitors
EP1984337B1 (fr) 2006-01-25 2014-04-30 Synta Pharmaceuticals Corp. Dérivés de vinyl-phényl utilisés dans le traitement et la prévention de troubles inflammatoires et immuns
EP2079694B1 (fr) 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. Composés d'hétérocycloalkyloxybenzamide n-substitués, et procédés d'utilisation
CA2685029A1 (fr) * 2007-04-26 2008-11-06 Avalon Pharmaceuticals Composes polycycliques et leurs utilisations
JP2008303155A (ja) * 2007-06-06 2008-12-18 Ube Ind Ltd Ｎ−（ω−フルオロアルキル）環状アミン化合物の製法、並びに新規なＮ−（４−フルオロブチル）環状アミン化合物及びその製法
JP2009035537A (ja) * 2007-07-10 2009-02-19 Nippon Synthetic Chem Ind Co Ltd:The Ｎ−置換アニリン誘導体及び１−置換インドール誘導体の製造方法
WO2010036908A1 (fr) * 2008-09-26 2010-04-01 Eisai R & D Management Co., Ltd. Utilisation de composés benzoxazole dans le traitement du paludisme
CN102272120B (zh) * 2008-11-07 2013-12-25 H.隆德贝克有限公司 生物活性酰胺
EP2404902A1 (fr) * 2009-03-05 2012-01-11 Shionogi&Co., Ltd. Dérivés de la pipéridine et de la pyrrolidine dotés d'un antagonisme pour les récepteurs npy y5
EP2519517B1 (fr) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase raf de type ii
WO2013010679A1 (fr) 2011-07-15 2013-01-24 Novartis Ag Sels d'éthers diaryliques aza-bicycliques et procédés pour fabriquer ceux-ci ou leurs précurseurs
CA2857969A1 (fr) * 2012-01-25 2013-08-01 Demerx, Inc. (1r,4r) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene et ses derives
CN106459489B (zh) 2014-05-21 2019-07-12 索尔维特殊聚合物美国有限责任公司 稳定剂化合物
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3273966B1 (fr) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
TW201710251A (zh) * 2015-05-27 2017-03-16 諾福根有限公司 作為抗癌藥劑之經官能化及取代之吲哚
EP3347018B1 (fr) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinases cycline-dépendantes
JP2017137259A (ja) * 2016-02-03 2017-08-10 株式会社Ihi 有機化合物の製造方法
CN109071542B (zh) 2016-02-19 2021-07-20 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物
CN106543089A (zh) * 2016-11-04 2017-03-29 山东铂源药业有限公司 一种达沙替尼中间体的合成方法
CN107892656A (zh) * 2017-10-27 2018-04-10 苏州盖德精细材料有限公司 一种2,5‑二氨基苯乙醇的制备方法
EP3810132A4 (fr) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. Inhibiteurs de kinase de la famille taire et utilisations correspondantes
MX2022003237A (es) * 2019-09-17 2022-07-04 Bial R&D Invest S A Imidazol carboxamidas sustituidas y su uso en el tratamiento de trastornos medicos.
KR102234530B1 (ko) * 2020-09-01 2021-03-31 대한민국 신규 톨트라주릴 유도체 및 이를 포함하는 쿠도아충 예방·치료를 위한 약학 조성물
CN115215787A (zh) * 2021-04-19 2022-10-21 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其用途
CN117003672B (zh) * 2023-08-09 2024-05-28 湖南正量工程技术有限公司 一种boc-4，4’-二硝基二苯胺的制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064394A1 (fr) * 1998-06-08 1999-12-16 Schering Corporation Antagonistes des recepteurs y5 neuropeptidiques
WO2000068201A1 (fr) * 1999-05-08 2000-11-16 Astrazeneca Ab Derives quinoline inhibiteurs d'enzymes mek
WO2003009845A1 (fr) * 2001-07-26 2003-02-06 Schering Corporation Antagonistes du recepteur y5 du neuropeptide y d'uree substituee
US20030027862A1 (en) * 2000-08-04 2003-02-06 Helmut Haning Amino-and amido-diphenyl ethers
WO2003072577A1 (fr) * 2002-02-28 2003-09-04 F.Hoffmann-La Roche Ag Derives thiazoles utilises comme antagonistes du recepteur npy
WO2004110368A2 (fr) * 2003-06-06 2004-12-23 Merck & Co., Inc. Polytherapie pour le traitement de l'hypertension

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06248153A (ja) * 1993-03-01 1994-09-06 Shin Etsu Chem Co Ltd 難燃樹脂組成物
SE9703414D0 (sv) * 1997-09-23 1997-09-23 Astra Ab New compounds
JP2000287697A (ja) * 1999-02-05 2000-10-17 Shionogi & Co Ltd Ｎｐｙ受容体親和性を有するラクトン誘導体
WO2002022592A2 (fr) * 2000-09-14 2002-03-21 Schering Corporation Antagonistes du recepteur y.y5 de neuropeptide d'urease substitue
WO2004007437A1 (fr) * 2002-07-11 2004-01-22 Aventis Pharma Deutschland Gmbh Acylurees substituees par uree et urethane, procedes permettant de les produire et leur utilisation comme medicaments

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064394A1 (fr) * 1998-06-08 1999-12-16 Schering Corporation Antagonistes des recepteurs y5 neuropeptidiques
WO2000068201A1 (fr) * 1999-05-08 2000-11-16 Astrazeneca Ab Derives quinoline inhibiteurs d'enzymes mek
US20030027862A1 (en) * 2000-08-04 2003-02-06 Helmut Haning Amino-and amido-diphenyl ethers
WO2003009845A1 (fr) * 2001-07-26 2003-02-06 Schering Corporation Antagonistes du recepteur y5 du neuropeptide y d'uree substituee
WO2003072577A1 (fr) * 2002-02-28 2003-09-04 F.Hoffmann-La Roche Ag Derives thiazoles utilises comme antagonistes du recepteur npy
WO2004110368A2 (fr) * 2003-06-06 2004-12-23 Merck & Co., Inc. Polytherapie pour le traitement de l'hypertension

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889690B2 (en) 2007-04-27 2014-11-18 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9365563B2 (en) 2007-04-27 2016-06-14 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof
US9273043B2 (en) 2011-06-22 2016-03-01 Purdue Pharma L.P. TRPV1 antagonists including dihydroxy substituent and uses thereof

Also Published As

Publication number Publication date
CN101198604A (zh) 2008-06-11
NI200700260A (es) 2009-03-03
CR9514A (es) 2008-08-26
ECSP077894A (es) 2008-03-26
JP2008538749A (ja) 2008-11-06
AP2007004218A0 (en) 2007-10-31
MX2007012847A (es) 2008-03-25
WO2006108965A2 (fr) 2006-10-19
US20090233910A1 (en) 2009-09-17
EP1879887A2 (fr) 2008-01-23
IL186601A0 (en) 2008-01-20
EA200800157A1 (ru) 2008-04-28
AU2006234413A1 (en) 2006-10-19
KR20080009112A (ko) 2008-01-24
CA2604773A1 (fr) 2006-10-19
FR2884516A1 (fr) 2006-10-20
MA29444B1 (fr) 2008-05-02
TNSN07376A1 (en) 2009-03-17
NO20075322L (no) 2008-01-11
FR2884516B1 (fr) 2007-06-22

Similar Documents

Publication Publication Date Title
WO2006108965A3 (fr) Antagonistes npy, preparation et utilisations
DE502005006149D1 (de) Hetaryloxy-substituierte phenylaminopyrimidine als rho-kinasehemmer
WO2007025069A3 (fr) Diazaspirodecane utilise comme antagonistes de recepteurs d'orexine
TW200612926A (en) Compounds and compositions as ppar modulators
WO2007126934A3 (fr) Antagonistes des récepteurs de l'orexine sous forme de composés amidoéthylthioéther
EP2305640A3 (fr) Diphenyl-éthers, -amines, -sulfides et -méthanes pour le traitement de maladies respiratoires
MA31451B1 (fr) Antagonistes des recepteurs de l'orexine de pyridyl piperidine.
TW200800976A (en) New compounds for the treatment of neurological, psychiatric or pain disorders
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2006084176A3 (fr) Composes et compositions utilises comme modulateurs de ppar
WO2006096434A3 (fr) Compositions pharmaceutiques permettant de traiter et/ou de prevenir les troubles de l'anxiete
ATE453642T1 (de) Substituierte phenylaminopyrimidine
TN2011000171A1 (en) Isonicotinamide orexin receptor antagonists
WO2007019234A3 (fr) Antagonistes des recepteurs d'orexine a base de sulfamide d'aminoethane
WO2007067511A3 (fr) Antagonistes de recepteur de prokineticine de morpholine-carboxamide
WO2007056366A3 (fr) Composes et compositions utilises en tant que modulateurs des ppar
WO2006058868A3 (fr) Pteridines substituees destinees au traitement de maladies inflammatoires
DE602006017574D1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
GEP20094844B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors
WO2005072308A3 (fr) Antagonistes des recepteurs du cgrp
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2007058805A3 (fr) Compositions et procedes destines au traitement des troubles du snc
TW200611695A (en) Pyrrolopyridine derivatives
TW200600505A (en) Compounds and compositions as ppar modulators
GEP20094843B (en) 3-aminocyclopentane carboxamides as modulators of chemokine receptors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2604773

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 186601

Country of ref document: IL

Ref document number: 12007502255

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/012847

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008505929

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 562774

Country of ref document: NZ

Ref document number: 8214/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2006743700

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: AP/P/2007/004218

Country of ref document: AP

WWE Wipo information: entry into national phase

Ref document number: DZP2007000670

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2006234413

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020077026216

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 07119362

Country of ref document: CO

Ref document number: CR2007-009514

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 2007142180

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2006234413

Country of ref document: AU

Date of ref document: 20060414

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006234413

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200680021275.7

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006743700

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200800157

Country of ref document: EA

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0608778

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL, TENDO EM VISTA A IMPOSSIBILIDADE DE ACEITACAO DA ENTRADA NA FASE NACIONAL, EM FACE DA NAO APRESENTACAO DE PELO MENOS UM QUADRO REIVINDICATORIO TRADUZIDO, CONFORME ATO NORMATIVO NO 128, DE 05/03/1997, ITEM 9.2, CABENDO DESARQUIVAMENTO

WWE Wipo information: entry into national phase

Ref document number: 11918470

Country of ref document: US

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载